Table 4 Baseline characteristics and echocardiographic data of patients with or without a significant improvement in LVEF (>10%) at follow-up

Male

80%

70%

0.09

Age (years)

61

61

0.75

Clinical history

Angina

44%

49%

0.50

Myocardial infarction

7%

7%

0.96

Percutaneous coronary intervention

5%

5%

0.86

Coronary artery bypass graft

0%

0%

-

In-hospital and follow-up

Anterior infarction

38%

39%

0.81

Thrombolysis

51%

51%

0.93

Peak creatine kinase (U/L)

1802 ± 1439

1567 ± 1245

0.22

Peak creatine kinase-MB (U/L)

185 ± 150

166 ± 159

0.39

Pathological Q waves (n)^†

2.1 ± 1.76

1.9 ± 1.58

0.53

Persistent ST elevation > 1 mm^†

34%

32%

0.67

Revascularization before follow-up

43%

62%

0.008

Echocardiography

Viable segments (16 segments model) (n)

2.3 ± 1.71

3.2 ± 1.78

<0.001

LVEDV (ml)

89.34 ± 32.44

99.84 ± 27.78

0.012

LVESV (ml)

38.91 ± 21.12

54.84 ± 22.03

<0.001

LV EF (%)

57.66 ± 10.93

45.87 ± 10.31

<0.001

WMI

1.51 ± 0.25

1.62 ± 0.31

0.01

follow-up echocardiogram (days)

208 ± 133

201 ± 127

0.70

Risk factors

Diabetes mellitus

9%

12%

0.50

Hypertension

29%

24%

0.35

Hypercholesterolemia

16%

17%

0.83

Current cigarette smoking

46%

47%

0.91

Family history of coronary artery disease

26%

29%

0.61

Medications at admission

Aspirin

12%

13%

0.74

Beta-blocker

13%

13%

0.96

Statins

10%

12%

0.60

ACE-inhibitor

11%

7%

0.27

Angiotensin II antagonist

7%

3%

0.09

Medications at discharge

Aspirin

94%

95%

0.80

Beta-blocker

95%

93%

0.73

Statins

95%

95%

0.96

ACE-inhibitor

57%

63%

0.36

Angiotensin II antagonist

6%

5%

0.80

Clopidogrel

32%

45%

0.08

Diuretics

8%

9%

0.79